[Level of evidence for therapeutic drug monitoring for paclitaxel].

Fiche publication


Date publication

mai 2010

Auteurs

Membres identifiés du Cancéropôle Est :
Dr ROYER Bernard


Tous les auteurs :
Gerritsen-van Schieveen P, Royer B

Résumé

Paclitaxel is an anticancer drug which displays pharmacokinetic properties which can lead to therapeutic drug monitoring requirement. The most effective pharmacokinetic parameter seems to be the time during which the plasma concentration is over 0.05 micromol/L. However, this target needs to be validated with new weekly schedules of administration. These reasons lead to consider the level of evidence of therapeutic drug monitoring of paclitaxel as potentially useful.

Référence

Therapie. 2010 May-Jun;65(3):195-200